Biostatsforce

biostatsforce applies a model-informed value-based approach to drug discovery & development aimed to identify and quantify drug liability as early as possible due to lack of efficacy, safety issues, tolerability and/or commercial unviability and to profile, differentiate and substantiate the value proposition of your product from an early stage where data is still limited. this framework should contribute to reduce drug attrition rate by introducing an advanced decision making approach consisting of a combination of different mechanistic and empirical modeling & simulation techniques to successfully predict drug efficacy & safety profile, strategic drug differentiation and early cost-effectiveness to secure commercial viability. by providing pharmaceutical companies with the synergic combination of strategic tools such as pbpk/pd, model-based meta-analysis, clinical trial simulations and early economic evaluations as part of our quantitative model-informed value based approach, biostat